Navigation Links
Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
Date:5/18/2010

CALGARY, AB, May 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a paper entitled "Two-Stage Phase I Dose-Escalation Study of Intratumoural Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers," has been published in the online version of the journal Clinical Cancer Research.

The paper covers final results from a Phase Ia/Ib U.K. clinical trial (REO 006) investigating the intratumoural delivery of REOLYSIN(R) in combination with radiation to treat patients with advanced cancers. A total of 23 patients received a range of two to six intratumoural doses of REOLYSIN at escalating dosages up to a maximum of 1x10(10) TCID(50) with a constant localized radiation dose of either 20 Gy or 36 Gy. The principal investigator for the study is Dr. Kevin Harrington from The Institute of Cancer Research and The Royal Marsden Hospital, London, U.K.

Of the seven evaluable patients in the low-dose (20Gy) radiation group, two patients had a partial response (PR) (esophageal adenocarcinoma and squamous cell carcinoma (SCC) of the skin) and five had stable disease (SD) including patients with malignant melanoma, pancreatic adenocarcinoma, SCC of the larynx and SCC of the skin (2). In the high-dose (36Gy) radiation group, five of seven evaluable patients had PRs (malignant melanoma (2), lung adenocarcinoma, colorectal adenocarcinoma, and ovarian adenocarcinoma) and two had SD (malignant melanoma).

"All 14 patients considered evaluable for treatment response in this study had SD or better for a clinical benefit rate of 100%," said Dr.

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
2. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
3. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
4. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
5. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
6. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
7. Oncolytics Biotech(R) Inc. Announces Unit Offering
8. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
10. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
11. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/w48l6t/global_cancer ... "Global Cancer Biosimilars Market Opportunity Outlook" report ... cancer biosimilar is required because they have both ... dominated the cancer segment for several decade but ... few years. They are biologic in origin and ...
(Date:6/26/2015)... DALLAS , June 26, 2015 ... Animal Fat), Application (Hydraulic Fluids, Metalworking fluids, Chainsaw oils, ... Automobile) & by Region - Global trends and Forecasts ... expected to reach $2,972.13 Million by 2020 at a ... Browse 160 market data Tables and   66 ...
(Date:6/25/2015)... 2015 Last June, a dedicated global team of ... using large-scale genome sequencing. Their research, which was written on ... journal Cell (Park 2015) , reveals critical ... months of the recent Ebola outbreak. Today Authorea ... workflows, and full edit history of the paper are ...
(Date:6/25/2015)... , June 25, 2015 Current asthma ... immune cells or by dilating the airways, can ... Children,s Hospital, Brigham and Women,s Hospital and Harvard ... controlling asthma: targeting certain sensory nerve endings in ... Reporting online in the journal Neuron ...
Breaking Biology Technology:Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3Biolubricants Market Worth $2,972.13 Million by 2020 2Biolubricants Market Worth $2,972.13 Million by 2020 3Open Science Takes Major Leap Forward 2Targeting Nerve Endings To Curb Allergic Asthma 2Targeting Nerve Endings To Curb Allergic Asthma 3Targeting Nerve Endings To Curb Allergic Asthma 4Targeting Nerve Endings To Curb Allergic Asthma 5
... 11 CV Therapeutics,Inc. (Nasdaq: CVTX ) today ... 2007 after the market closes on Tuesday, November 6,2007. ... p.m. EST,1:30 p.m. PST, on the company,s website. ... the Company,s website at, http://www.cvt.com and go to ...
... - The Board of,Directors of Immunotec Inc. is ... A. Northrop as President and Chief Executive Officer, ... Board of Directors of Immunotec Inc., Mr. Northrop ... success in rapid growth,situations, Mr. Northrop has impressive ...
... an Eden Prairie-,based molecular diagnostics service and technology company, ... its CFO, and Elizabeth A. Skinner,as VP - Legal, ... of Edwin Watts Golf, and has previously,served as VP ... Allied Signal,Aerospace, and corporate controller of NCR Corporation. He ...
Cached Biology Technology:CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2Immunotec Inc. announces appointment of President & CEO James A. Northrop 2Access Genetics Announces New Executive Appointments 2
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... touch fingerprint sensors in the company,s portfolio from one of ... are planned to mainly take place during the third quarter ... Asia . Jörgen Lantto, CEO ... of    the   growing interest from smartphone OEMs in ...
(Date:6/15/2015)... YORK , June 15, 2015 ... today from Telstra reveals the majority of US consumers using ... them via biometrics, such as fingerprint and voiceprint, instead of ... According to Telstra,s " Mobile Identity   - ... " report, with smartphones now the primary channel used ...
(Date:6/11/2015)... 11, 2015 Daon, a global leader ... its IdentityX Mobile Authentication Platform v4.0 has been ... is an industry consortium launched in 2013 to ... stronger authentication.  In order to receive certification, a ... series of tests that measure compliance and ensure ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... Group, Inc. (OTC Bulletin Board: MDXG ), ... biomaterial-based products, announced today that its results for the ... and Company guidance will be released after the closing ... timing of the earnings announcement allows MiMedx time to ...
... the oocysts from the Cryptosporidium genus and cysts ... greatest public health problems in water supply, because these parasites ... Hermida, a scientist at the Galician Institute for Food Quality ... A team led by this researcher took 232 water samples ...
... at IRB Barcelona have completed the 3D structural sequence ... substances between the extra and intracellular milieu. This finding ... occur in these relevant proteins during basic cell processes, ... cell volume, and nerve transmission. The exchange ...
Cached Biology News:MiMedx Group, Inc. Announces Release Date for 2010 Fourth Quarter and Full Year Results 2Parasitic protozoons survive waste water and drinking water treatment plants in Galicia 2Researchers achieve a full film frame of a family of proteins essential for cell function 2
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... for relax positively and negatively supercoiled DNA in ... , Studying the effects of supercoiling on transcription ... vitro , Determining the degree of supercoiling ... plasmids that differ in length by only one ...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Biology Products: